Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
- 3 What about ezitimibe for cardiovascular disease and stroke prevention
- 4 What are the main safety risks of ezetimibe+statin (e.g., cancer)?
- 5 What about ezetimibe without statin? Is it an effective therapy?
- 6 How much LDL lowering and heart-risk reduction does ezetimibe monotherapy achieve?
- 7 Is ezetimibe alone effective in lowering apoB?
- 8 What is the best way to lower apoB dramatically without a statin
- 9 What are the side effects and risks of PCSK9 inhibitors vs ezetimibe?
Answered on this page ↓
What are the side effects and risks of PCSK9 inhibitors vs ezetimibe?
The short version: PCSK9 inhibitors and ezetimibe have similar overall side-effect profiles in trials, but PCSK9 inhibitors add injection-site reactions, and the long-term safety data is thinner than the marketing suggests.
The most direct comparison comes from a meta-analysis of 25 randomized trials: adverse events did not differ significantly between PCSK9 inhibitors and placebo or ezetimibe [1]. A separate meta-analysis of 10 trials in 50,053 statin-treated patients found no difference in overall adverse events versus ezetimibe, but injection-site reactions were about 55% more common with PCSK9 inhibitors [4]. That is the clearest practical difference: one drug is a pill, the other is a shot that stings.
The bigger concern is mortality. One systematic review of ClinicalTrials.gov data found evolocumab was associated with increased all-cause mortality in the FOURIER trial, with a number-needed-to-harm of about 200 [2]. The same review found no overall reduction in individual cardiovascular or non-cardiovascular events [2]. A 2020 meta-analysis found no clear mortality benefit for PCSK9 inhibitors versus placebo [4]. Ezetimibe, by contrast, showed no significant differences in myopathy, rhabdomyolysis, liver enzyme elevations, or cancer in the 18,144-patient IMPROVE-IT trial [3].
| Side effect | PCSK9 inhibitors | Ezetimibe |
|---|---|---|
| Injection-site reactions | ~55% more common vs placebo/ezetimibe [4] | Not applicable (pill) |
| All-cause mortality | Evolocumab: increased in FOURIER (NNH ~200) [2] | No signal in IMPROVE-IT [3] |
| Myopathy | No significant difference vs placebo [4] | 0.2% vs 0.1% with statin alone [3] |
| Overall adverse events | No significant difference vs ezetimibe [1][4] | No significant difference [1] |
The evidence base is conflicted. The FOURIER trial was manufacturer-funded, and the meta-analyses inherit that bias [1][2]. Long-term safety data beyond a few years is still pending [1]. Ezetimibe has a decade more of real-world use and a hard clinical-outcome trial in 18,144 patients [3].
My call: for side-effect risk, ezetimibe is the safer choice; PCSK9 inhibitors add injection-site reactions and carry a mortality signal that has not been explained away. Confidence: moderate.
Sources used 4
-
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
This narrative review concludes that PCSK9 inhibitors markedly lower LDL-C and reduce cardiovascular events in high-risk patients, with apparent safety and possible pleiotropic benefits, though long-term outcome data were still pending.
DOI: 10.1155/2018/3179201 -
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
Systematic review of PCSK9 inhibitors using ClinicalTrials.gov data finds no overall reduction in individual cardiovascular or non-cardiovascular events, with evolocumab associated with increased all-cause mortality in the FOURIER trial and alirocumab reducing all-cause serious …
DOI: 10.1080/17512433.2020.1787832 -
High‐risk patients benefit from lowering of LDL‐cholesterol
The IMPROVE-IT trial showed that adding ezetimibe to simvastatin significantly reduced major cardiovascular events in high-risk post-acute coronary syndrome patients, supporting further LDL-cholesterol lowering.
DOI: 10.1002/psb.1304 -
Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
A systematic review and meta-analysis of 10 randomized controlled trials (50,053 statin-treated patients with cardiovascular risk) shows PCSK9 inhibitors modestly reduce cardiovascular events, nonfatal myocardial infarction, and ischemic stroke, with no clear mortality benefit, …
DOI: 10.18433/jpps31197